Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | 6-phosphofructokinase | 0.011 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0065 | 0.0396 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0065 | 0.0396 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0065 | 0.0396 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.011 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0108 | 0.9604 | 0.9604 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.011 | 1 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.011 | 1 | 1 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.0065 | 0.0396 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.011 | 1 | 1 |
Onchocerca volvulus | 0.011 | 1 | 0.5 | |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.011 | 1 | 1 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.0065 | 0.0396 | 0.5 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.011 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
-Log I50 (functional) | = 0 | Antisecretory dose in mg/kg required for 50% inhibition in dogs by intravenous administration | ChEMBL. | 2866245 |
Inhibition (functional) | = 50 % | Maximum percent inhibition of acid output in pentagastrin-stimulated Heidenhain pouch dog following 1 mg/kg i.v. administration. | ChEMBL. | 2866245 |
KB (functional) | = 0.000000562 | Dissociation constant of H2 receptor antagonist activity against guinea pig atrium | ChEMBL. | 2866245 |
KB (functional) | = 0.000000562 | Dissociation constant of H2 receptor antagonist activity against guinea pig atrium | ChEMBL. | 2866245 |
logP (ADMET) | = 0.694 | Partition coefficient (logP) | ChEMBL. | 2866245 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.